[ARIA] ARIAD Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 12.22 Change: 0.35 (2.95%)
Ext. hours: Change: 0 (0%)

chart ARIA

Refresh chart

Description: ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancer

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 98.06% Sales Growth - Q/Q-64.1% P/E-149.94
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.5% ROE-434.69% ROI-39.48%
Current Ratio3.97 Quick Ratio3.96 Long Term Debt/Equity1.45 Debt Ratio2.25
Gross Margin96.06% Operating Margin-136.24% Net Profit Margin-140.67% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.05 M Cash From Investing Activities-750 K Cash From Operating Activities-50.19 M Gross Profit23.3 M
Net Profit-52.68 M Operating Profit-49.7 M Total Assets580.45 M Total Current Assets340.91 M
Total Current Liabilities85.82 M Total Debt376.31 M Total Liabilities542.39 M Total Revenue23.99 M
Technical Data
High 52 week23.99 Low 52 week4.48 Last close23.99 Last change0%
RSI76.56 Average true range1.75 Beta1.54 Volume1.88 M
Simple moving average 20 days0.65% Simple moving average 50 days24.35% Simple moving average 200 days93.85%
Performance Data
Performance Week0.17% Performance Month1.01% Performance Quart72.71% Performance Half132.69%
Performance Year372.24% Performance Year-to-date92.85% Volatility daily0.22% Volatility weekly0.49%
Volatility monthly1% Volatility yearly3.46% Relative Volume151.81% Average Volume9.6 M
New High New Low


2018-03-23 09:03:43 | Incyte’s Revenue Stream in 4Q17

2018-01-08 09:35:30 | What to watch during health-care investing's biggest week of the year

2017-08-22 07:36:25 | Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

2017-07-10 09:06:27 | What Sprycel Could Mean for Bristol-Myers Squibb

2017-06-27 16:38:08 | ?SEC charges two former Ariad executives with insider trading

2017-06-15 07:37:06 | Analyzing Incyte’s Revenue Streams in 1Q17

2017-04-06 06:41:15 | Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale

2017-03-15 11:35:00 | After Soaring to $150, Can Incyte Stir Up More Upside?

2017-03-01 10:36:44 | Who Is Incyte Collaborating With?

2017-02-28 14:35:43 | Understanding Incyte’s Revenue Stream for 2016

2017-02-16 16:14:42 | ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o

2017-02-16 08:55:00 | Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

2017-02-15 14:44:00 | Two Great Stock Ideas in the IBB Biotech ETF

2017-02-07 08:16:01 | ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

2017-02-06 16:06:26 | ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2017-02-06 13:30:44 | Why Ariad Pharmaceuticals Stock Nearly Doubled in January

2017-02-06 11:25:00 | Ariad Submits Marketing Application to EU Agency

2017-02-06 07:35:00 | ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

2017-02-01 08:15:00 | Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan

2017-02-01 01:00:00 | Takeda Reports Q3 FY2016 Results and Improves Year-End Outlook

2017-01-30 16:12:10 | Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool

2017-01-26 07:37:12 | Varian Medical VAR Misses on Q1 Earnings and Revenues

2017-01-25 10:45:06 | Ariad mum on layoffs in letter to employees: ‘It’s business as usual’

2017-01-20 17:25:54 | Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC

2017-01-20 17:25:54 | Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC

2017-01-20 14:55:05 | Ariad played hardball to boost Takeda buyout price, federal filings show

2017-01-20 07:00:47 | Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017

2017-01-20 04:40:09 | Can The Uptrend Continue for ARIAD Pharmaceuticals ARIA?

2017-01-19 15:00:00 | Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc.

2017-01-18 16:41:08 | 5 Expensive Drugs That Could End Up in Trump's Crosshairs

2017-01-18 16:41:08 | 5 Expensive Drugs That Could End Up in Trump's Crosshairs

2017-01-18 10:48:00 | Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders

2017-01-18 08:44:01 | Jazz Begins Phase III Study for Label Expansion of Defitelio

2017-01-18 08:22:01 | Becton, Dickinson Commercially Launches Precise WTA Kits

2017-01-17 08:58:00 | These 3 Stocks Have Doubled Since Election Day

2017-01-13 20:22:00 | Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap Friday 1/13/17

2017-01-13 17:18:00 | ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. ARIA Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited

2017-01-13 08:21:09 | These 3 Stocks Quadrupled in Just 1 Year

2017-01-13 08:00:01 | ArQule ARQL Catches Eye: Stock Moves 7.2% Higher

2017-01-13 07:29:12 | ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

2017-01-11 07:10:08 | Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'

2017-01-10 15:06:07 | ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D

2017-01-10 12:21:07 | After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next

2017-01-10 11:45:47 | Ariad Pharm upgraded by Barclays

2017-01-10 09:45:07 | [$$] Japan's Takeda Looks to More Acquisitions to Fuel Global Growth

2017-01-10 09:27:02 | 4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal

2017-01-10 08:43:01 | ARIAD Pharma Stock Gains on Acquisition Deal with Takeda

2017-01-10 08:00:29 | Takeda Takes the Hard Road

2017-01-10 05:01:04 | Takeda Pharmaceutical Company Limited -- Moody's reviews Takeda Pharmaceutical's ratings for downgrade

2017-01-10 02:08:27 | Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal